Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho’s Jared Holz

February 29, 2024
Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho’s Jared HolzEli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho’s Jared Holz

CNBC’s Melissa Lee and Jared Holz, Mizuho Americas healthcare sector strategist, join ‘Squawk on Street’ to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk will remain the frontrunners for the next 2-3 years, and more.

Share This

Latest Mizuho News

Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

April 20, 2026
Iran war highlights risks in the chemical supply chain

Iran war highlights risks in the chemical supply chain

April 15, 2026
Wall Street jumps to near one-month highs after US-Iran ceasefire

Wall Street jumps to near one-month highs after US-Iran ceasefire

April 8, 2026

Mizuho news from around the globe

back-to-top-blue